Bio-Rad Laboratories (BIO) EBIT Margin (2009 - 2026)

Bio-Rad Laboratories (BIO) has reported EBIT Margin for 18 consecutive years, with 11.15% the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBIT Margin fell 68.0% year-over-year to 11.15% in Q2 2026; TTM through Jun 2026 was 2.05%, a 670.0% decrease from a year earlier, with the FY2025 full-year figure at 1.83%, down 865.0% from the prior year.
• EBIT Margin was 11.15% for Q2 2026 at Bio-Rad Laboratories, up from 5.76% in the prior quarter.
• Over five years, EBIT Margin peaked at 20.91% in Q1 2022 and troughed at 17.15% in Q4 2025.
• A 5-year average of 10.39% and a median of 11.49% in 2026 frame the typical range for EBIT Margin.
• Across the five-year window, EBIT Margin soared 703 bps in 2022 and sank 2589 bps in 2025, its largest moves.
• Over 5 years, EBIT Margin stood at 16.25% in 2022, then dropped by 14 bps to 13.99% in 2023, then plunged by 38 bps to 8.73% in 2024, then plunged by 296 bps to 17.15% in 2025, then jumped by 165 bps to 11.15% in 2026.
• The last three EBIT Margin figures came in at 11.15% (Q2 2026), 5.76% (Q1 2026), and 17.15% (Q4 2025), per Business Quant data.